Completed PHASE2 INTERVENTIONAL 1-arm NCT00433069

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

A Pilot Study of Treatment With Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (With the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study)

Sponsor: University Hospital, Geneva

Conditions Chronic Hepatitis C

Interventions Interferon Alfa-2a Pioglitazone Ribavirin

Updated 5 times since 2017 Last updated: May 27, 2015 Started: Jan 31, 2007 Primary completion: Dec 31, 2007 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Hepatitis C, this trial is completed. The trial is conducted by University Hospital, Geneva and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Geneva

Data source: University Hospital, Geneva

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland